TScan Therapeutics (TCRX) Change in Account Payables (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly Change in Account Payables came in at $1.0 million in Q1 2026, up 87.28% year-on-year from $558000.0 in Q1 2025, and up 120.62% on a QoQ basis from -$5.1 million in Q4 2025.
TScan Therapeutics (TCRX) Change in Account Payables (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 7 years of Change in Account Payables data on file, last reported at $1.0 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 87.28% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 185.21% decrease from a year earlier, with the FY2025 full-year figure at -$3.0 million, down 251.0% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.0 million, up from -$5.1 million in the prior quarter.
- Over the last five years, Change in Account Payables for TCRX reached as high as $1.9 million in Q3 2025 and fell as low as -$5.1 million in Q4 2025.
- Historically, Change in Account Payables has averaged $29647.1 across 5 years, with a median of $408000.0 in 2022.
- Across the five-year window, Change in Account Payables surged 475.46% in 2024 and slumped 615.46% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at $414000.0 in 2022, then slumped by 254.83% to -$641000.0 in 2023, then surged by 253.35% to $983000.0 in 2024, then slumped by 615.46% to -$5.1 million in 2025, then surged by 120.62% to $1.0 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $1.0 million in Q1 2026, -$5.1 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 16.86 Mn |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Mn |
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | -5.07 Mn |
| Dec 31, 2025 | -5.07 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | -435,000.00 |
| Jun 30, 2025 | -435,000.00 |
| Mar 31, 2025 | 558,000.00 |
| Mar 31, 2025 | 558,000.00 |
| Dec 31, 2024 | 983,000.00 |
| Dec 31, 2024 | 983,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 396,000.00 |
| Mar 31, 2024 | -410,000.00 |
| Mar 31, 2024 | -410,000.00 |
| Dec 31, 2023 | -641,000.00 |
| Dec 31, 2023 | -641,000.00 |